India's draft rule classifying diagnostic AI as a higher-risk Class C medical device could reshape how fast hospitals can deploy tools like Apollo's AI stroke-imaging system.
Apollo Hospitals in India is using AI to read stroke brain scans in about two minutes instead of an hour, even as regulators move to classify diagnostic AI tools as higher-risk medical devices.
Billions have poured into AI drug discovery deals, but no AI-discovered drug has yet won full FDA approval — a gap that will test whether the technology's promise translates into real medicines.
Takeda has signed a $600 million deal with Insilico Medicine and a $1.7 billion deal with Iambic Therapeutics, betting heavily on AI to refill its drug development pipeline.
Wearable startup CUDIS launched a smart ring with an AI coach that rewards users with redeemable points for healthy habits, part of a wider push to gamify wellness tracking and boost engagement.
Eli Lilly struck a deal worth up to $2.75 billion with Insilico Medicine to bring AI-developed drugs to market, kicking off a wave of major pharma AI partnerships that followed throughout the year.
Novo Nordisk partnered with OpenAI to apply AI analysis to drug discovery, betting general-purpose AI models can help it stay ahead in the fiercely competitive obesity and diabetes drug market.
Eli Lilly signed a deal worth up to $2.25 billion with AI gene-editing company Profluent, extending its aggressive multi-platform bet on AI drug discovery across several distinct technology approaches.
The University of Texas System struck an enterprise-wide deal to expand Abridge's ambient AI scribe across all eight of its health institutions after a pilot saw clinician usage grow 73% in a year.
GSK licensed a cellular-biology foundation model from UK biotech Relation Therapeutics in a deal worth up to $110 million, part of a wider pharma shift toward licensing specialized AI platforms.